An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation

Condition:   Asthma
Interventions:   Drug: Reslizumab;   Drug: Fludeoxyglucose F 18 (FDG);   Drug: Placebo
Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
Not yet recruiting – verified October 2016

View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days